Coronary heart disease (CHD), caused by atherosclerosis, is one of the main causes of disability and mortality throughout the world, including in Uzbekistan. This article represents the results of optomozes therapy of patients with stable angina based on the early diagnostics of renal dysfunction. As a result of treatment, positive clinical dynamics were observed in both groups, but in the second group this result was more pronounced. It has been shown that early detection of renal dysfunction markers and combined lipid-lowering agents in combination with traditional therapy in patients with stable angina is more reliably effective than monotherapy.

atherosclerosis, coronary heart disease, risk factor, dyslipidemia, statins, impaired renal function, glomerular filtration rate, cystatin S, creatinine.

Alekseeva IA, Ezhov MV. Osobennosti primeneniya fixirovannoy kombinatsii rozuvastatina i ezetimiba dlya effektivnoy hypolipi demicheskoy therapy. Medytsinsky Soviet . 2020; (14):26–32). doi : 10.21518/2079–701X-2020–14–26–32 .

Ahmedzhanov N.M., Nebieridze D.V., Safaryan A.S. Correction of hypercholesterolemia and primary and secondary prevention of cardiovascular disease: osobennosti and controversial issues. Ratsionalnaya Pharmacoterapiya v Kardiologii 2018;14(6): 917-921. DOI:10.20996/1819-6446-2018-14-6-917-921.

Barbarash O.L., Kashtalap V.V. Upravlenie riskom razvitiya ishemicheskikh sobytiy and patients with multifocal atherosclerosis and diabetes mellitus type 2. Atherothrombosis . 2020;(1):34–44. doi : 10.21518/2307-1109-2020-1-34-44;

Belyalov F.I. Ischemic disease serdtsa and impaired renal function - 2017 . - No. 13(3) . - S. 409 - 415.

Bakirov B. A., Hasanov A. H., Davletshin R. A., Nurmukhametova R. A., Kudlay D. A. Cluster characteristics of comorbid manifestations and patients of middle age with multifocal atherosclerosis in groups of high blood pressure. Cardiology. 2019;59(7):31–36.

Vasilkova O. N., Pchelin I. Yu., Mokhort T. V. Tsistatin S is a marker of active development of atherosclerotic processes in patients with diabetes and chronic kidney disease. Regional circulation and microcirculation. 2022;21(3):26–32. Doi:10.24884/1682-6655-2022-21-3-26-32 .

Diagnostics and correction of disordered lipid exchange with cerebrovascular disease and prevention of atherosclerosis. Rossiyskie rekomendatsii, VII review. Atherosclerosis and dyslipidemia. 2020;1(38):7–42.): 10.34687/2219–8202.JAD.2020.01.0002.

Ezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., Bajan S.S. i dr. Diagnostics and correction of disordered lipid exchange with cerebrovascular disease and prevention of atherosclerosis. Rossiyskie rekomendatsii VI peresmotr. Atherosclerosis dyslipidemia . 2017;3:5 -22;

Karpov Yu.A., Barbarash O.L., Boshchenko A.A., Kashtalap V.V., Kuharchuk V.V., Mironov V.M., Panchenko E.P., Ruda M.M., Samko A. .N, Soboleva G.N., Shiryaev A.A. Eurasian clinical recommendations for diagnosis and treatment of patients with stable ischemic disease (2020-2021). Eurasian cardiology journal. 2021; (3):54-93, https://doi.org/10.38109/2225-1685-2021-3-54-93 .

Pogosova N. V., Yufereva Yu. M., Kachanova N. P., Metelskaya V. A., Koltunov I. E., Voronina V. P. i dr. Poisk vozmojnykh podkhodov k diagnostice do klinicheskogo atherosclerosis u lits s vysokim serdechno-sosudistym riskom. Cardiology. 2019;59(11S):53–62.

Sergienko I. V. _ Ezhov M. V. _ Gurevich V. S. _ I so author Sravnitelnaya effektivnost i bezopasnost monotherapy statinami i ix kombinatsii s ezetimibom (Resultaty rossiyskogo retrospectivenogo nablyudatelnogo issledovaniya UNISON). Atherosclerosis and dyslipidemia. 2022;4(49):25–38. DOI: 10.34687/2219-8202. JAD.2022.04.0003.

Sumin A.N., Korok E.V., shcheglova A.V., Barbarash O.L. Comorbidity in patients with coronary heart disease: gender specifics. Rational pharmacotherapy and cardiology 2017;13(5):622-629. DOI: 10.20996/1819-6446-2017-13-5- 622-629.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidemias : lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111–88

Mach F., Baigent C., Catapano A., Koskinas K., Casula M., Badimon L. et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111–188. doi : 10.1093/ eurheartj /ehz455.

Neeland IJ, Ross R., Després JP, Matsuzawa Y., Yamashita S., Shai I., Seidell J., Magni P., Santos RD, Arsenault B., et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement. Lancet Diabetes Endocrinol . 2019; 7 : 715–725. doi : 10.1016/S2213-8587(19)30084-1.

Rovin BH et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases //Kidney international. - 2021. - T. 100. - no. 4. – S. 753-779.

Schoppet , M., Rauner , M., Benner, J., Chapurlat , R., Hofbauer , LC, & Szulc , P. (2015). Serum fetuin-A levels and abdominal aortic calcification in healthy men - The STRAMBO study. Bone, 79 , 196-202. doi : 10.1016/j.bone.2015.06.004;

Van der Laan S., Fall T., Soumaré A., et al. Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study // J Am Coll Cardiol , 2016. Vol. 68(9). P. 934–945. doi:10.1016/ j.jacc.2016.05.092 .

Li Q., Zeng Y., Jiang Q., Wu C., Zhou J. 2019. Role of mTOR signaling in the regulation of high glucose-induced podocyte injury. Exp. Ther . Med . 17 (4), 2495–2502. https://doi.org/10.3892/etm.2019.7236 ;

Kim S., Hwang S., Jang HR et al. Creatinine- and cystatin C-based estimated glomerular filtration rate slopes for the prediction of kidney outcome: a comparative retrospective study // BMC Nephrol .— 2019.—Vol. 20 (1)—P. 214.

Deng Y., Wang L., Hou Y. et al. The influence of glycemic status on the performance of cystatin C for acute kidney injury detection in the critically ill // Ren. File. — 2019. — Vol. 41 (1) — P. 139–149.